DAX23.087 +2,6%ESt505.285 +2,4%Top 10 Crypto12,45 -1,2%Dow41.317 +1,4%Nas17.978 +1,5%Bitcoin85.267 -0,5%Euro1,1296 ±0,0%Öl61,45 -0,7%Gold3.240 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Tesla A1CX3T Microsoft 870747 Amazon 906866 Siemens Energy ENER6Y BASF BASF11 RENK RENK73 Palantir A2QA4J Apple 865985 Allianz 840400 Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Bank 514000 Bayer BAY001
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Wall Street letztlich im Plus -- DAX geht über 23.000-Punkte-Marke ins Wochenende -- Amazon verdient mehr als erwartet -- Siemens Energy setzt Rekordrally fort -- Apple, Airbus, Mercedes-Benz im Fokus
Top News
Die Highlights im TecDAX: Gewinner und Verlierer der KW 18 im Überblick Die Highlights im TecDAX: Gewinner und Verlierer der KW 18 im Überblick
Warren Buffetts Berkshire Hathaway mit starkem Gewinnrückgang - Harsche Kritik an Trumps-Zollpolitik Warren Buffetts Berkshire Hathaway mit starkem Gewinnrückgang - Harsche Kritik an Trumps-Zollpolitik
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

UCB Aktie

NeuKaufenVerkaufen
UCB Aktien-Sparplan
169,10 EUR +13,30 EUR +8,54 %
STU
170,15 EUR +9,55 EUR +5,95 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.32,16 Mrd. EUR

KGV34,29Div. Rendite0,51%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN852738

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINBE0003739530

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolUCBJF

UCB Aktien News

DatumMeistgelesen
PR NewswireUCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
GlobeNewswireUCB Convening Notice to the General Meeting of the Shareholders 2025
PR NewswireNew data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
Wer­bungUCB-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireEpilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
PR NewswireBIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
PR NewswireBIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
PR NewswireOn Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
PR NewswireUCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
PR NewswireUCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
PR NewswireUCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
PR NewswireUCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
PR NewswireNew BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
PR NewswireUCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) S...
PR NewswireUCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
PR NewswireUCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
PR NewswireUCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
PR NewswireUCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
PR NewswireNew insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease
BenzingaJohnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
BenzingaBelgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
BenzingaBelgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
PR NewswireUCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")
PR NewswireFINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia
PR NewswireNew CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels
PR NewswireUCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024
PR NewswireUCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa
PR NewswireUCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting
PR NewswireUCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa
PR NewswireFDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations
GlobeNewswireUCB Convening Notice to the General Meeting of the Shareholders 2024
PR NewswireFirst Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
PR NewswireBIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
PR NewswireUCB on Growth Path for a Decade Plus
PR NewswireZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
PR NewswireUCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting
PR NewswireUCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
PR NewswirePost Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)
PR NewswireUCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023
PR NewswireUCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Founda...
PR NewswireNAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters
Wer­bung

UCB News

UCB News: auf dieser Seite finden Sie alle UCB News und Nachrichten zur UCB Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch UCB News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um UCB News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.